IDiyas

For the Inventor, By the Inventor

Takarazuka, Japan

Kenji Irie

USPTO Granted Patents = 7

Average Co-Inventor Count = 7.5

ph-index = 6

Forward Citations = 122(Granted Patents)


Location History:

  • Takarazuka, JA (1977)
  • Takarazuka, JP (1978 - 1979)
  • Kawanishi, JP (1993)
  • Nishinomiya, JP (1997)

Company Filing History:

goldMedal6 out of 6,892 
 
Sumitomo Chemical Company, Limited
 patents
silverMedal2 out of 174 
 
Sumitomo Pharmaceuticals Company Limited
 patents
where one patent can have more than one assignee

Years Active: 1977-1997

Loading Chart...
7 patents (USPTO):Explore Patents
1. 5646154 - Pharmaceutical compositions for inhibiting the formation of tumor (1997-07-08),
2. 5196337 - Human monoclonal antibody, and its production and use (1993-03-23),
3. 4160087 - N-acylamino-.alpha.-arylacetamido cephalosporins (1979-07-03),
4. 4156724 - N-acylamino-alpha-arylacetamido cephalosporins and antibacterial (1979-05-29),
5. 4117126 - 7-(.alpha.-(4-Hydroxy-1,5-naphthyridine-3-carbonamido)-.alpha.-ph (1978-09-26),
6. 4061748 - 7-(.alpha.-(4 (1977-12-06),
7. 4046904 - Novel penicillin, and its preparation and use (1977-09-06),

Title: Kenji Irie: Innovator in Pharmaceutical Research

Introduction

Kenji Irie is a prominent inventor based in Takarazuka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of monoclonal antibodies. With a total of seven patents to his name, Irie's work has had a profound impact on medical research and treatment.

Latest Patents

Among his latest patents, Irie has developed pharmaceutical compositions aimed at inhibiting tumor formation. One notable patent involves a human monoclonal antibody that has both prophylactic and therapeutic effects against infectious diseases caused by Pseudomonas aeruginosa. This antibody targets specific epitopes located in the O-antigen of serotypes A and H of the bacteria. Additionally, his patents include processes for producing hybridomas that generate these human monoclonal antibodies.

Career Highlights

Throughout his career, Kenji Irie has worked with esteemed organizations such as Sumitomo Chemical Company and Sumitomo Pharmaceuticals. His experience in these companies has allowed him to collaborate on groundbreaking research and development projects in the pharmaceutical industry.

Collaborations

Irie has collaborated with notable colleagues, including Hiroshi Noguchi and Hirotada Yamada. These partnerships have further enhanced his research capabilities and contributed to the advancement of innovative medical solutions.

Conclusion

Kenji Irie is a distinguished inventor whose work in pharmaceutical research continues to influence the medical field. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…